Adverum Biotechnologies, Inc. (0HA3.L)
- Previous Close
9.52 - Open
10.02 - Bid --
- Ask --
- Day's Range
9.59 - 10.11 - 52 Week Range
0.69 - 10.11 - Volume
216 - Avg. Volume
27,079 - Market Cap (intraday)
7.777M - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
-- - EPS (TTM)
-1.58 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
adverum.com121
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0HA3.L
Performance Overview: 0HA3.L
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0HA3.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0HA3.L
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.14%
Return on Equity (ttm)
-88.43%
Revenue (ttm)
3.6M
Net Income Avi to Common (ttm)
-117.17M
Diluted EPS (ttm)
-1.58
Balance Sheet and Cash Flow
Total Cash (mrq)
96.53M
Total Debt/Equity (mrq)
89.90%
Levered Free Cash Flow (ttm)
-60.69M
Company Insights: 0HA3.L
0HA3.L does not have Company Insights